Published in Nat Rev Clin Oncol on October 01, 2013
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid | NCT00295646
Study of Statin as Neo-Adjuvant Therapy in Postmenopausal Breast Cancer | NCT00816244
The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer (2015) 2.74
The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. PLoS One (2015) 1.76
Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med (2014) 1.62
Drug repurposing in oncology-patient and health systems opportunities. Nat Rev Clin Oncol (2015) 1.25
Stem cells from adipose tissue and breast cancer: hype, risks and hope. Br J Cancer (2015) 0.90
Statin use and risk of liver cancer: an update meta-analysis. BMJ Open (2014) 0.85
Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genet (2015) 0.82
Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells. EBioMedicine (2016) 0.81
Systematic review with network meta-analysis: statins and risk of hepatocellular carcinoma. Oncotarget (2016) 0.79
Statin Use and Its Impact on Survival in Pancreatic Cancer Patients. Medicine (Baltimore) (2016) 0.78
Targeting Inflammation in Cancer Prevention and Therapy. Cancer Prev Res (Phila) (2016) 0.78
New concepts and challenges in the clinical translation of cancer preventive therapies: the role of pharmacodynamic biomarkers. Ecancermedicalscience (2015) 0.78
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib. Oncotarget (2015) 0.78
Anti-inflammatory and Antitumor Activity of a Triple Therapy for a Colitis-Related Colorectal Cancer. J Cancer (2016) 0.78
Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem (2017) 0.77
Association of Metformin Use With Cancer-Specific Mortality in Hepatocellular Carcinoma After Curative Resection: A Nationwide Population-Based Study. Medicine (Baltimore) (2016) 0.76
Statin Use and Breast Cancer Risk in the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Metformin and Prostate Cancer: a New Role for an Old Drug. Curr Urol Rep (2017) 0.75
Statins and pancreatic cancer. Oncol Lett (2017) 0.75
Chemoprevention of cancer: current evidence and future prospects. F1000Res (2015) 0.75
Statins Dose-Dependently Exert Significant Chemopreventive Effects Against Various Cancers in Chronic Obstructive Pulmonary Disease Patients: A Population-Based Cohort Study. J Cancer (2016) 0.75
Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study. Oncotarget (2016) 0.75
From rapalogs to anti-aging formula. Oncotarget (2017) 0.75
The Pharmacological Profile of a Novel Highly Potent Bisphosphonate, OX14 (1-Fluoro-2-(Imidazo-[1,2-α]Pyridin-3-yl)-Ethyl-Bisphosphonate). J Bone Miner Res (2017) 0.75
Statins intake and risk of liver cancer: A dose-response meta analysis of prospective cohort studies. Medicine (Baltimore) (2017) 0.75
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med (1996) 23.76
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
Regulation of the mevalonate pathway. Nature (1990) 18.25
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science (2005) 12.35
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia (2009) 10.95
A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature (1998) 10.35
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Statin use and reduced cancer-related mortality. N Engl J Med (2012) 8.51
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res (2007) 7.42
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res (2009) 6.74
Statins and cancer risk: a meta-analysis. JAMA (2006) 6.28
New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care (2009) 6.17
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol (2011) 5.63
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst (2005) 5.32
Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial. Lancet (2011) 5.08
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 5.05
Statins as a newly recognized type of immunomodulator. Nat Med (2000) 5.00
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ (2010) 4.92
Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology (2009) 4.72
Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med (2011) 4.51
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet (2010) 4.42
Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) (2010) 4.36
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell (2012) 4.09
Statins and the risk of cancer after heart transplantation. Circulation (2012) 4.06
Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov (2005) 3.92
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care (2010) 3.68
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 3.59
Cancer risk among statin users: a population-based cohort study. Int J Cancer (2005) 3.50
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst (2008) 3.40
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 3.38
Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA (2010) 3.37
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med (2000) 3.31
Oral bisphosphonate use and breast cancer incidence in postmenopausal women. J Clin Oncol (2010) 3.17
Statin safety: a systematic review. Am J Cardiol (2006) 3.14
A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 3.13
Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate--Danish National Register Based Cohort Study. Osteoporos Int (2012) 3.13
Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care (2012) 3.11
The risk of cancer in users of statins. J Clin Oncol (2004) 3.01
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol (2002) 3.01
The role of aspirin in cancer prevention. Nat Rev Clin Oncol (2012) 2.94
Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. Cancer Res (2011) 2.93
Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873). J Natl Cancer Inst (2007) 2.86
Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med (2001) 2.85
Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One (2012) 2.84
Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology (2012) 2.74
Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74
Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. J Clin Oncol (2012) 2.66
Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial. Lancet Oncol (2012) 2.65
Time-window bias in case-control studies: statins and lung cancer. Epidemiology (2011) 2.56
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol (2004) 2.48
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41
Statins are associated with a reduced risk of hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology (2009) 2.39
Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther (2002) 2.36
Statin use and cancer risk in the General Practice Research Database. Br J Cancer (2004) 2.34
Use of bisphosphonates and risk of postmenopausal breast cancer. J Clin Oncol (2010) 2.33
Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst (2011) 2.27
Post-diagnosis statin use and breast cancer recurrence in a prospective cohort study of early stage breast cancer survivors. Breast Cancer Res Treat (2007) 2.27
Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet (2012) 2.26
The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila) (2008) 2.23
Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol (2012) 2.22
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res (2007) 2.18
Diabetes and lung cancer among postmenopausal women. Diabetes Care (2012) 2.17
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol (2012) 2.16
Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest (2007) 2.15
Statins and cancer: A systematic review and meta-analysis. Eur J Cancer (2008) 2.15
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
Reduced risk of colorectal cancer with use of oral bisphosphonates: a systematic review and meta-analysis. J Clin Oncol (2012) 2.09
Breast cancer growth prevention by statins. Cancer Res (2006) 2.09
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer (2010) 2.04
Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol (2008) 2.03
Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care (2003) 2.02
Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia (2011) 2.00
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer (2008) 1.96
The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer (2010) 1.91
Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial. Breast Cancer Res Treat (2011) 1.90
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) (2010) 1.86
Cholesterol-lowering drugs and colorectal cancer incidence in a large United States cohort. J Natl Cancer Inst (2006) 1.84
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Bisphosphonates: from bench to bedside. Ann N Y Acad Sci (2006) 1.82
Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res (2011) 1.76
Dysregulation of the mevalonate pathway promotes transformation. Proc Natl Acad Sci U S A (2010) 1.71
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
Preventive therapy for breast cancer: a consensus statement. Lancet Oncol (2011) 1.69
Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells. Cell Cycle (2009) 1.66
Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat (2012) 1.66
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care (2011) 1.65
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat (2008) 1.64
Future directions in cancer prevention. Nat Rev Cancer (2012) 1.62
Statins and the risk of colorectal cancer. N Engl J Med (2005) 6.86
Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nat Genet (2008) 6.75
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Replication of lung cancer susceptibility loci at chromosomes 15q25, 5p15, and 6p21: a pooled analysis from the International Lung Cancer Consortium. J Natl Cancer Inst (2010) 3.18
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet (2013) 2.39
Meta-analysis of new genome-wide association studies of colorectal cancer risk. Hum Genet (2011) 2.35
Genetic variation in 8q24 associated with risk of colorectal cancer. Cancer Biol Ther (2007) 2.32
A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet (2002) 2.24
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2009) 2.13
Vitamin D status in primary hyperparathyroidism. Eur J Intern Med (2011) 2.05
Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs. Genet Epidemiol (2008) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Clinical phenotype of families with longevity. J Am Geriatr Soc (2004) 2.03
Phenotype of microsatellite unstable colorectal carcinomas: Well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol (2003) 1.97
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. PLoS Genet (2013) 1.88
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76
Accurate classification of MLH1/MSH2 missense variants with multivariate analysis of protein polymorphisms-mismatch repair (MAPP-MMR). Hum Mutat (2008) 1.76
The relationship between serum 25(OH)D and parathyroid hormone levels. Am J Med (2011) 1.70
MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res (2011) 1.68
Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. PLoS Genet (2010) 1.56
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer. Cancer Prev Res (Phila) (2010) 1.45
Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ (2011) 1.38
Smoking, gender, and ethnicity predict somatic BRAF mutations in colorectal cancer. Cancer Epidemiol Biomarkers Prev (2010) 1.31
The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer. Nat Genet (2004) 1.25
Pathologic predictors of microsatellite instability in colorectal cancer. Am J Surg Pathol (2009) 1.23
The public prefers fecal occult blood test over colonoscopy for colorectal cancer screening. Eur J Cancer Prev (2008) 1.22
FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev (2008) 1.22
Accurate molecular classification of human cancers based on gene expression using a simple classifier with a pathological tree-based framework. Am J Pathol (2003) 1.20
Genetic anthropology of the colorectal cancer-susceptibility allele APC I1307K: evidence of genetic drift within the Ashkenazim. Am J Hum Genet (2003) 1.16
Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res (2009) 1.15
BRCA germline mutations in Jewish women with uterine serous papillary carcinoma. Gynecol Oncol (2004) 1.14
Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol (2011) 1.12
Increased risk of lung cancer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer (2012) 1.07
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients. Cancer (2011) 1.03
Gene expression differences between colon and rectum tumors. Clin Cancer Res (2011) 1.03
The effect of statins on risk and survival of gynecological malignancies. Gynecol Oncol (2013) 1.03
Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res (2006) 1.01
Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control (2010) 0.98
K-ras mutations in sporadic colorectal tumors in Israel: unusual high frequency of codon 13 mutations and evidence for nonhomogeneous representation of mutation subtypes. Dig Dis Sci (2002) 0.97
Vascular disorders preceding diagnosis of cancer: distinguishing the causal relationship based on Bradford-Hill guidelines. Angiology (2003) 0.95
The risk of all-cause mortality is inversely related to serum 25(OH)D levels. J Clin Endocrinol Metab (2012) 0.94
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res (2005) 0.91
BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst (2015) 0.90
Associated Links Among Smoking, Chronic Obstructive Pulmonary Disease, and Small Cell Lung Cancer: A Pooled Analysis in the International Lung Cancer Consortium. EBioMedicine (2015) 0.90
Aspirin and NSAID use and lung cancer risk: a pooled analysis in the International Lung Cancer Consortium (ILCCO). Cancer Causes Control (2011) 0.89
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res (2014) 0.89
Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2007) 0.88
RNASEL mutation screening and association study in Ashkenazi and non-Ashkenazi prostate cancer patients. Cancer Epidemiol Biomarkers Prev (2006) 0.88
Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst (2005) 0.88
FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genet Cytogenet (2009) 0.87
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet (2011) 0.87
The association between obesity and urinary tract infection. Eur J Intern Med (2012) 0.86
Clustering women's health behaviors. Health Educ Behav (2002) 0.86
Excellent performance of Hemoccult Sensa in organised colorectal cancer screening. Eur J Cancer (2012) 0.86
The longitudinal variability of serum 25(OH)D levels. Eur J Intern Med (2012) 0.85
Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer (2010) 0.85
Calcium supplementation provides an extended window of opportunity for bone mass accretion after menarche. Am J Clin Nutr (2003) 0.84
Quality control in a National Program for the Early Detection of Breast Cancer: women's satisfaction with the mammography process. Womens Health Issues (2008) 0.84
Low integrated DNA repair score and lung cancer risk. Cancer Prev Res (Phila) (2013) 0.83
N-methylpurine DNA glycosylase and OGG1 DNA repair activities: opposite associations with lung cancer risk. J Natl Cancer Inst (2012) 0.83
The use of exercise stress testing for the management of low-risk patients with chest pain. Am J Emerg Med (2009) 0.83
Polymorphisms in alcohol metabolism genes ADH1B and ALDH2, alcohol consumption and colorectal cancer. PLoS One (2013) 0.82
High risk of colorectal and endometrial cancer in Ashkenazi families with the MSH2 A636P founder mutation. Gastroenterology (2011) 0.81
Maternal mosaicism for a second mutational event--a novel deletion--in a familial adenomatous polyposis family harboring a new germ-line mutation in the alternatively spliced-exon 9 region of APC. Hum Mutat (2002) 0.81
Dietary intake of carotenoid isomers in Israel. Int J Vitam Nutr Res (2007) 0.81
Low allele frequency of MLH1 D132H in American colorectal and endometrial cancer patients. Dis Colon Rectum (2005) 0.81
International collaborations in cancer control and the Third International Cancer Control Congress. Tumori (2009) 0.81
Recreational physical activity modifies the association between a common GH1 polymorphism and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 0.80
BRCA1 breast cancer risk is modified by CYP19 polymorphisms in Ashkenazi Jews. Cancer Epidemiol Biomarkers Prev (2009) 0.80
APC E1317Q is not associated with Colorectal Cancer in a population-based case-control study in Northern Israel. Cancer Epidemiol Biomarkers Prev (2006) 0.80
Sustained effect of short-term calcium supplementation on bone mass in adolescent girls with low calcium intake. Am J Clin Nutr (2005) 0.80
Vitamin D Status in Israeli subjects before the initiation and after the cessation of vitamin D supplements. Calcif Tissue Int (2011) 0.79
Common MUTYH mutations and colorectal cancer risk in multiethnic populations. Fam Cancer (2012) 0.78
PTPRJ haplotypes and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 0.78
The evaluation of vitamin D status in normocalcemic primary hyperparathyroidism. Eur J Intern Med (2012) 0.78
The rationale for delaying aging and the prevention of age-related diseases. Rambam Maimonides Med J (2012) 0.78
Fecal occult blood test performance indicators in warfarin-treated patients. Dis Colon Rectum (2010) 0.78
Unraveling seasonality in population averages: an examination of seasonal variation in glucose levels in diabetes patients using a large population-based data set. Chronobiol Int (2011) 0.78
Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations. Eur J Cancer Prev (2009) 0.78
Self-rated health is prospectively associated with uptake of screening for the early detection of colorectal cancer, not vice versa. Eur J Cancer Prev (2016) 0.78
APC I1307K and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 0.77
Gynecologic malignancies in Ashkenazi families with the MSH2 A636P founder mutation. Am J Obstet Gynecol (2008) 0.77
Statins, aspirin and risk of venous thromboembolic events in breast cancer patients. J Thromb Thrombolysis (2014) 0.76
Corrigendum: Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun (2015) 0.76
BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report. Gynecol Oncol (2005) 0.76
Bisphosphonates: beyond prevention of bone metastases. J Natl Cancer Inst (2011) 0.75
Are we getting closer to molecular population screening for colorectal cancer? J Natl Cancer Inst (2009) 0.75
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst (2017) 0.75
Inference of the haplotype effect in a matched case-control study using unphased genotype data. Int J Biostat (2008) 0.75
Cancer prevention: from public health interventions to individual tailoring. Eur J Cancer Prev (2007) 0.75
BRCA1/2 mutation carriers: living with susceptibility. Community Genet (2003) 0.75
Antithrombotic therapy for prevention of stroke in clinical practice in the ED. Am J Emerg Med (2007) 0.75
Evaluation of chest pain in the ED: factors affecting triage decisions. Am J Emerg Med (2003) 0.75